Sommario

• • ·Influenza vaccine shake-up

    Pagina :1323

     
• • ·The superiority of bivalent over monovalent booster vaccines

    Pagina :1324-1325

    Ronen Arbel, Yael Wolff-Sagy

     
• • ·Are bivalent vaccines better than ancestral-virus monovalent vaccines in protecting against severe omicron COVID-19?

    Pagina :1325-1327

    Shabir A Madhi, Daniel R Feikin

     
• • ·A promising candidate for a universal influenza vaccine

    Pagina :1327-1329

    Irina Isakova-Sivak, Larisa Rudenko

     
• • ·A new era for equity in meningococcal disease prevention

    Pagina :1329-1330

    Bing Wang, Helen S Marshall

     
• • ·The quest for a cytomegalovirus vaccine continues

    Pagina :1330-1332

    Flavia Chiuppesi, Felix Wussow

     
• • ·Targeting vulnerable populations for tuberculosis: does one size fit all?

    Pagina :1332-1333

    Leonardo Martinez, Alberto L Garcia-Basteiro

     
• • ·Developing a vaccine against Sudan virus disease

    Pagina :1333-1335

    Daniela Manno

     
• • ·Mpox: interdependence and inequity

    Pagina :1335-1336

    Emmanuel Nakoune, Felicité Emma Moussa Yagata, Aimee Nimbona, Marie-Roseline Darnycka Belizaire, Yap Boum

      
• • ·Dengue fever: working towards global control considering biological, social, and planetary determinants

    Pagina :e506

    Fernando Bellissimo-Rodrigues, Amaury Lelis Dal Fabbro

    
• • ·The US–Mexico border, migration crisis, and falciparum malaria

    Pagina :e507

    Ana Patricia Rendón-Hernández, Luis Esteban Ramírez-González, Mayte Martínez-Velázquez, Claudia Vázquez-Zamora, Beatriz Leal-Escobar, José Luis Soto-Hernández

    
• • ·Virus isolation and neutralisation of SARS-CoV-2 variants BA.2.86 and EG.5.1

    Pagina :e509

    Ria Lassaunière, Charlotta Polacek, Magdalena Utko, Karina M Sørensen, Sharmin Baig, Kirsten Ellegaard, Leandro A Escobar-Herrera, Anders Fomsgaard, Katja Spiess, Vithiagaran Gunalan, Marc Bennedbæk, Jannik Fonager, Olivier Schwartz, Delphine Planas, Etienne Simon-Lorière, Uffe V Schneider, Raphael N Sieber, Marc Stegger, Lene Nielsen, Morten Hoppe, Tyra G Krause, Henrik Ullum, Pikka Jokelainen, Morten Rasmussen

      
• • ·Correction to Lancet Infect Dis 2023; published online Sept 28. https://doi.org/10.1016/S1473-3099(23)00493-0

    Pagina :e511

    
• • ·Highlights from IDWeek 2023

    Pagina :e512

    Phoebe Downes

    
• • ·Highlights from ASTMH 2023

    Pagina :e513

    Marco De Ambrogi

     
• • ·Boost for COVID-19 testing in the USA

    Pagina :e514

    Sanjeet Bagcchi

     
• • ·Cholera in Sudan

    Pagina :e515

    Udani Samarasekera

    
• • ·UK Covid-19 Inquiry

    Pagina :e516

    Talha Burki

     
• • ·Infectious diseases surveillance update

    Pagina :e518

    Tanzina Islam

    Mappa Mappa
• • ·Research in brief

    Pagina :e519

    Sharmila Devi

    Mappa Mappa
• • ·Hoosen Jerry Coovadia

    Pagina :1337

    Clemence Manyukwe

     
• • ·Robert A Lamb

    Pagina :1338

    Sanjeet Bagcchi

     
• • ·Khitam Muhsen—tackling infection inequalities in Israel

    Pagina :1339

    Tony Kirby

     
• • ·A pandemic playbook

    Pagina :1340

    Vijay Shankar Balakrishnan

     
• • ·Tsogolo La Thanzi

    Pagina :1341

    Hollie Sherwood-Martin

     
• • ·COVID-19 in the USA

    Pagina :1342

    Sanjeet Bagcchi

     
• • ·Effectiveness of bivalent mRNA vaccines against medically attended symptomatic SARS-CoV-2 infection and COVID-19-related hospital admission among SARS-CoV-2-naive and previously infected individuals: a retrospective cohort study

    Pagina :1343-1348

    Celine Y Tan, Calvin J Chiew, Deanette Pang, Vernon J Lee, Benjamin Ong, Lin-Fa Wang, Ee Chee Ren, David Chien Lye, Kelvin Bryan Tan

    Riassunto Riassunto Mappa Mappa  
• • ·Relative effectiveness of monovalent and bivalent mRNA boosters in preventing severe COVID-19 due to omicron BA.5 infection up to 4 months post-administration in people aged 60 years or older in Italy: a retrospective matched cohort study

    Pagina :1349-1359

    Alberto Mateo-Urdiales, Chiara Sacco, Emmanouil Alexandros Fotakis, Martina Del Manso, Antonino Bella, Flavia Riccardo, Marco Bressi, Maria Cristina Rota, Daniele Petrone, Andrea Siddu, Giorgio Fedele, Paola Stefanelli, Anna Teresa Palamara, Silvio Brusaferro, Giovanni Rezza, Patrizio Pezzotti, Massimo Fabiani

    Riassunto Riassunto Mappa Mappa   
• • ·Immunogenicity, safety, and preliminary efficacy evaluation of OVX836, a nucleoprotein-based universal influenza A vaccine candidate: a randomised, double-blind, placebo-controlled, phase 2a trial

    Pagina :1360-1369

    Isabel Leroux-Roels, Paul Willems, Gwenn Waerlop, Yorick Janssens, Jessika Tourneur, Fien De Boever, Jacques Bruhwyler, Azhar Alhatemi, Bart Jacobs, Florence Nicolas, Geert Leroux-Roels, Alexandre Le Vert

    Riassunto Riassunto Mappa Mappa   
• • ·Immunogenicity and safety of a pentavalent meningococcal ABCWY vaccine in adolescents and young adults: an observer-blind, active-controlled, randomised trial

    Pagina :1370-1382

    James Peterson, Daniel Drazan, Hanna Czajka, Jason Maguire, Jean-Louis Pregaldien, IIkka Seppa, Roger Maansson, Robert O'Neill, Paul Balmer, Luis Jodar, Kathrin U Jansen, Annaliesa S Anderson, John L Perez, Johannes Beeslaar

    Riassunto Riassunto Mappa Mappa   
• • ·Safety, efficacy, and immunogenicity of a replication-defective human cytomegalovirus vaccine, V160, in cytomegalovirus-seronegative women: a double-blind, randomised, placebo-controlled, phase 2b trial

    Pagina :1383-1394

    Rituparna Das, Daniel Blázquez-Gamero, David I Bernstein, Soren Gantt, Oliver Bautista, Karen Beck, Anthony Conlon, Daniel I S Rosenbloom, Dai Wang, Michael Ritter, Beth Arnold, Paula Annunziato, Kevin L Russell, V160-002 study group

    Riassunto Riassunto Mappa Mappa   
• • ·Burden of tuberculosis among vulnerable populations worldwide: an overview of systematic reviews

    Pagina :1395-1407

    Stefan Litvinjenko, Olivia Magwood, Shishi Wu, Xiaolin Wei

    Riassunto Riassunto Mappa Mappa   
• • ·Safety, tolerability, and immunogenicity of the Ebola Sudan chimpanzee adenovirus vector vaccine (cAd3-EBO S) in healthy Ugandan adults: a phase 1, open-label, dose-escalation clinical trial

    Pagina :1408-1417

    Betty Mwesigwa, Katherine V Houser, Amelia R Hofstetter, Ana M Ortega-Villa, Prossy Naluyima, Francis Kiweewa, Immaculate Nakabuye, Galina V Yamshchikov, Charla Andrews, Mark O'Callahan, Larisa Strom, Steven Schech, Leigh Anne Eller, Erica L Sondergaard, Paul T Scott, Mihret F Amare, Kayvon Modjarrad, Amir Wamala, Allan Tindikahwa, Ezra Musingye, Jauhara Nanyondo, Martin R Gaudinski, Ingelise J Gordon, LaSonji A Holman, Jamie G Saunders, Pamela J M Costner, Floreliz H Mendoza, Myra Happe, Patricia Morgan, Sarah H Plummer, Somia P Hickman, Sandra Vazquez, Tamar Murray, Jamilet Cordon, Caitlyn N M Dulan, Ruth Hunegnaw, Manjula Basappa, Marcelino Padilla, Suprabhath R Gajjala, Phillip A Swanson, Bob C Lin, Emily E Coates, Jason G Gall, Adrian B McDermott, Richard A Koup, John R Mascola, Aurélie Ploquin, Nancy J Sullivan, Hannah Kibuuka, Julie A Ake, Julie E Ledgerwood, RV 508 Study Team, Jaqueline Namugabo, Claire Beingana, Maureen G. Mukyala, Joseph Wandege, Christine Nanteza, Brenda Atwijuka, Juliet Kizanye, Gertrude Nassanga, Joanita Namuli, Herbert Kityo, Mathias Ssekitoleko, Roy Nassaka, Hilda Mutebe, Mable Kabahubya, Alicia T. Widge, Sarah E. O'Connell, Obrimpong Amoa-Awua, Sandeep R. Narpala, Britta Flach, Josephine Cox, Allison Beck, Mercy Guech, Ellie Seo, Judy A. Stein

    Riassunto Riassunto Mappa Mappa   
• • ·Clinical characteristics and predictors of human mpox outcome during the 2022 outbreak in Nigeria: a cohort study

    Pagina :1418-1428

    Dimie Ogoina, Mahmood Muazu Dalhat, Ballah Akawu Denue, Mildred Okowa, Nneka Marian Chika-Igwenyi, Hakeem Abiola Yusuff, Umenzekwe Chukwudi Christian, Olukemi Adekanmbi, Anastacia Okwudili Ojimba, John Tunde Aremu, Kambai Lalus Habila, Sebastine Oseghae Oiwoh, Ekaete Alice Tobin, Simon Mafuka Johnson, Abimbola Olaitan, Chizaram Onyeaghala, Simji Samuel Gomerep, Datonye Alasia, Asukwo E Onukak, Juliet Mmerem, Uche Unigwe, Olanrewaju Falodun, Vivian Kwaghe, Sati Klein Awang, Mogaji Sunday, Chiedozie James Maduka, Aliyu Mamman Na'uzo, Sampson Omagbemi Owhin, Abdullahi Asara Mohammed, Mukhtar Abdulmajid Adeiza, Nigerian Infectious Diseases Society Mpox Study Group

    Riassunto Riassunto Mappa Mappa   
• • ·Simian malaria: a narrative review on emergence, epidemiology and threat to global malaria elimination

    Pagina :e520

    Kimberly M Fornace, Gabriel Zorello Laporta, Indra Vythilingham, Tock Hing Chua, Kamruddin Ahmed, Nantha K Jeyaprakasam, Ana Maria Ribeiro de Castro Duarte, Amirah Amir, Wei Kit Phang, Chris Drakeley, Maria Anice M Sallum, Yee Ling Lau

    Riassunto Riassunto Mappa Mappa   
• • ·Strategic and scientific contributions of human challenge trials for vaccine development: facts versus fantasy

    Pagina :e533

    Yara-Natalie Abo, Euzebiusz Jamrozik, James S McCarthy, Meta Roestenberg, Andrew C Steer, Joshua Osowicki

    Riassunto Riassunto Mappa Mappa   
• • ·Improving measurement of tuberculosis care cascades to enhance people-centred care

    Pagina :e547

    Lena Faust, Pren Naidoo, Guillermo Caceres-Cardenas, César Ugarte-Gil, Monde Muyoyeta, Andrew D Kerkhoff, Karikalan Nagarajan, Srinath Satyanarayana, Niaina Rakotosamimanana, Simon Grandjean Lapierre, Olusola Adedeji Adejumo, Joseph Kuye, Charity Oga-Omenka, Madhukar Pai, Ramnath Subbaraman

    Riassunto Riassunto Mappa Mappa  
• • ·Frequent screening for asymptomatic chlamydia and gonorrhoea infections in men who have sex with men: time to re-evaluate?

    Pagina :e558

    Eloise Williams, Deborah A Williamson, Jane S Hocking

    Riassunto Riassunto Mappa Mappa   
• • ·Coxsackievirus A6 pneumonia in a child

    Pagina :e567

    Jing Zhou, Ying Li, Qigai Yin, Angela Vinturache, Guodong Ding